PL378291A1 - Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin - Google Patents

Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin

Info

Publication number
PL378291A1
PL378291A1 PL378291A PL37829104A PL378291A1 PL 378291 A1 PL378291 A1 PL 378291A1 PL 378291 A PL378291 A PL 378291A PL 37829104 A PL37829104 A PL 37829104A PL 378291 A1 PL378291 A1 PL 378291A1
Authority
PL
Poland
Prior art keywords
cells
csf
dendritic
monocytes
dendritic cells
Prior art date
Application number
PL378291A
Other languages
English (en)
Other versions
PL209998B1 (pl
Inventor
Benjamin A. Tjoa
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL378291A1 publication Critical patent/PL378291A1/pl
Publication of PL209998B1 publication Critical patent/PL209998B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL378291A 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne PL209998B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
PCT/US2004/006119 WO2004076651A2 (en) 2003-02-27 2004-02-27 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Publications (2)

Publication Number Publication Date
PL378291A1 true PL378291A1 (pl) 2006-03-20
PL209998B1 PL209998B1 (pl) 2011-11-30

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378291A PL209998B1 (pl) 2003-02-27 2004-02-27 Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne

Country Status (20)

Country Link
US (4) US8389278B2 (pl)
EP (1) EP1604016B1 (pl)
JP (1) JP4762887B2 (pl)
KR (2) KR101201875B1 (pl)
CN (1) CN1784488B (pl)
AT (1) ATE420946T1 (pl)
AU (2) AU2004214896A1 (pl)
BR (1) BRPI0407900A (pl)
CA (1) CA2517295C (pl)
CY (1) CY1109099T1 (pl)
DE (1) DE602004019057D1 (pl)
DK (1) DK1604016T3 (pl)
ES (1) ES2321939T3 (pl)
IL (1) IL170512A (pl)
MX (1) MXPA05009178A (pl)
NZ (1) NZ542071A (pl)
PL (1) PL209998B1 (pl)
RU (1) RU2364625C2 (pl)
TW (1) TW200506061A (pl)
WO (1) WO2004076651A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN1738619B (zh) * 2002-12-06 2012-04-18 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
EP1957634A4 (en) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1806395A1 (en) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DK2328923T3 (en) * 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
ES2618573T3 (es) * 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
KR101911380B1 (ko) * 2009-07-24 2018-10-25 로드아일랜드하스피틀 아스파라기닐-β-히드록실라제 발현 종양을 위한 수지상 세포 백신
WO2011046832A2 (en) * 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
AU2011227447B2 (en) * 2010-03-15 2016-04-14 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
DK3173420T3 (da) * 2014-07-23 2021-10-18 Nat Ct Nanoscience & Technology China Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
CA2990640A1 (en) * 2015-06-30 2017-01-05 Northwest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
KR20180044430A (ko) * 2015-09-15 2018-05-02 노쓰웨스트 바이오써라퓨틱스, 인크. 진행성 암을 가진 대상체를 위한 활성화된 수지상 세포 조성물 및 면역요법적 치료와 관련된 방법
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
WO2019246111A1 (en) 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
IL286907B2 (en) * 2019-04-03 2025-11-01 Akron Bioproducts Llc Cryopreservation and cell culture media
CA3148229A1 (en) * 2019-07-12 2021-01-21 Kyushu University, National University Corporation Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
US20220401535A1 (en) * 2019-11-18 2022-12-22 Children's Medical Center Corporation Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
JP7652461B2 (ja) * 2021-05-07 2025-03-27 ナノファエンテック カンパニー リミテッド 樹状細胞の培養方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230288400A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72829T1 (de) * 1985-06-11 1992-03-15 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
PT2322603T (pt) * 2001-09-06 2020-01-21 Northwest Biotherapeutics Inc Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1
DK2298436T3 (da) 2002-06-19 2014-11-10 Northwest Biotherapeutics Inc Brug af en tangentiel flowfiltreringsenhed og metoder til leukocytberigelse
BRPI0407002A (pt) * 2003-02-10 2006-01-10 Northwest Biotherapeutics Inc Células cultivadas que apresentam antìgeno cd14+

Also Published As

Publication number Publication date
US20210102169A1 (en) 2021-04-08
IL170512A (en) 2013-12-31
EP1604016B1 (en) 2009-01-14
EP1604016A2 (en) 2005-12-14
HK1086597A1 (en) 2006-09-22
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
WO2004076651A3 (en) 2005-03-10
RU2364625C2 (ru) 2009-08-20
US10731130B2 (en) 2020-08-04
NZ542071A (en) 2007-11-30
JP4762887B2 (ja) 2011-08-31
KR20050107471A (ko) 2005-11-11
JP2006519021A (ja) 2006-08-24
US8389278B2 (en) 2013-03-05
US11827903B2 (en) 2023-11-28
RU2005129561A (ru) 2006-03-10
DE602004019057D1 (de) 2009-03-05
KR101201875B1 (ko) 2012-11-15
TW200506061A (en) 2005-02-16
CN1784488A (zh) 2006-06-07
AU2010201319A1 (en) 2010-04-29
ES2321939T3 (es) 2009-06-15
US9102917B2 (en) 2015-08-11
PL209998B1 (pl) 2011-11-30
US20130273654A1 (en) 2013-10-17
CN1784488B (zh) 2010-07-28
AU2010201319B2 (en) 2012-09-06
BRPI0407900A (pt) 2006-03-21
DK1604016T3 (da) 2009-05-18
CA2517295C (en) 2016-01-12
WO2004076651A2 (en) 2004-09-10
US20040203143A1 (en) 2004-10-14
AU2004214896A1 (en) 2004-09-10
KR20110106474A (ko) 2011-09-28
CA2517295A1 (en) 2004-09-10
EP1604016A4 (en) 2006-03-08
ATE420946T1 (de) 2009-01-15
CY1109099T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
PL378291A1 (pl) Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin
Li et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
SG149061A1 (en) Definitive endoderm
CN116004533B (zh) iNKT细胞的激活扩增方法及其培养基组合
Jegatheeswaran et al. Searching for the elusive regulatory innate lymphoid cell
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
EP2484759A3 (en) Methods of refolding mammalian glycosyltransferases
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
Löb et al. Are indoleamine-2, 3-dioxygenase producing human dendritic cells a tool for suppression of allogeneic T-cell responses?
CA2510596A1 (en) Dendritic cell line
EP2377922A3 (en) PDX1 expressing endoderm
WO2005023982A3 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
GanjiBakhsh et al. Mixture of fibroblast, epithelial and endothelial cells conditioned media induce monocyte-derived dendritic cell maturation
AU8478601A (en) Methods for culturing human lung mast cells and uses thereof
MX2007005928A (es) Metodos para la produccion de celulas de mamiferos.
Sánchez et al. Chemotherapy plus G‐CSF mobilized peripheral blood stem cell harvests from acute myeloid leukaemia patients contain large amounts of polyclonal myeloid linnegCD11cpos dendritic precursor cells
EP1927657A3 (en) Compositions and methods for producing antigen-presenting cells
CA2442300A1 (en) Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
WO2004067697A3 (en) Icos+ suppresser t cells
Liotta et al. IL-4 is crucial for the in vitro generation of mature dendritic cells obtained from human cord blood CD34^ sup+^ precursors
Sun et al. Aberrant dendritic cell differentiation initiated by the Mll-Een fusion gene does not require leukemic transformation
Leung Process of enriching adherent CD4+ T cells from monocyte depleted peripheral blood mononuclear cells with interleukin 2 and interleukin 4
Lee Generation and characterization of dendritic-like cells derived from translocation (9; 22) acute lymphoblastic leukemia blasts